Jaymin Kang, PharmD

LTG-001, an oral Nav1.8 selective inhibitor, works by blocking peripheral sensory neurons responsible for pain signaling.

Radiprodil, a negative allosteric N-methyl-D-aspartate receptor subtype 2B modulator, has been seen to have an antiseizure effect in preclinical seizure and epilepsy models.

By blocking dopamine-1 receptors, ecopipam is expected to reduce the repetitive and compulsive behaviors seen in Tourette syndrome.

The Fast Track designation is supported by data from the open-label phase 1 SNK01-MX04 trial, as well as preliminary data from the phase 1 cohort from the phase 1/2a SNK01-AD01 trial.

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for troriluzole for the treatment of adults with spinocerebellar ataxia (SCA).

Treatment with intravenous (IV) edaravone was associated with fewer reported disease progression milestones and deaths in patients with amyotrophic lateral sclerosis (ALS), according to real-world data published in the Journal of Comparative Effectiveness Research. ALS is a neurodegenerative condition that results in cell neuron death and progressive muscular weakness. The IV formulation of edaravone was…

Lecanemab is a humanized immunoglobulin gamma 1 monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta.

Activation of SIGMAR1 is expected to restore cellular homeostasis by inducing autophagy, which may slow neurodegeneration in patients with early AD.

The BLA was based on data from the open-label extension of the phase 3 Clarity AD study.

BRC-002 is an oral botanically-derived cannabinoid agent expected to reduce the pain and comorbidities associated with CRPS.

PTC518 is an orally taken small molecule discovered from RNA splicing technology.

Xanomeline and trospium chloride is a first-in-class medication that selectively targets the M1 and M4 receptors without blocking D2 receptors.